

19 March 2015 EMA/128095/2015 Veterinary Medicines Division

# Monthly report on application procedures, guidelines and related documents for veterinary medicines

February 2015

This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on:

- scientific advice requests;
- applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs);
- applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs);
- arbitration and referral procedures;
- requests for classification of products as Minor Use/Minor Species (MUMS)/limited market.

In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents.


The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.




# Statistics on pre- and post-authorisation applications for medicinal products for veterinary use

| Scientific advice requests | 5    |      |      |      |
|----------------------------|------|------|------|------|
|                            | 2012 | 2013 | 2014 | 2015 |
| Submitted                  | 28   | 40   | 31   | 2    |
| Advice given               | 29   | 34   | 33   | 5    |

# Scientific advice requests submitted and andvice given




| Initial evaluation of marketing authorisation applications |      |      |      |      |  |
|--|------|------|------|------|--|
|  | 2012 | 2013 | 2014 | 2015 |  |
| Full (submitted)   | 12   | 23   | 11   | 2    |  |
| Abridged/generics (submitted)                              | 0    | 0    | 1    | 1    |  |
| Withdrawals  | 1    | 0    | 3    | 0    |  |
| Positive opinions  | 9    | 12   | 20   | 1    |  |
| Negative opinions  | 0    | 0    | 0    | 1    |  |



■Full ■Abridged/generics

Pre-authorisation: submissions of MA applications by




Pre-authorisation: outcome of the evaluation of MA

| Marketing authorisations |      |      |      |      |  |
|--------------------------|------|------|------|------|--|
|                          | 2012 | 2013 | 2014 | 2015 |  |
| Granted                  | 8    | 13   | 19   | 3    |  |
| Withdrawals              | 3    | 3    | 1    | 0    |  |
| Not renewed              | 0    | 0    | 0    | 0    |  |

| Extensions — applications |      |      |      |      |  |
|---------------------------|------|------|------|------|--|
|                           | 2012 | 2013 | 2014 | 2015 |  |
| Submitted                 | 8    | 5    | 6    | 1    |  |
| Withdrawals               | 1    | 0    | 1    | 0    |  |
| Positive opinions         | 10   | 9    | 2    | 2    |  |
| Negative opinions         | 0    | 0    | 0    | 0    |  |

| Variations — applications submitted |      |      |      |      |  |
|-------------------------------------|------|------|------|------|--|
|                                     | 2012 | 2013 | 2014 | 2015 |  |
| Type-IA variations                  | 104  | 175  | 175  | 22   |  |
| Type-IB variations                  | 96   | 108  | 118  | 17   |  |
| Type-II variations                  | 52   | 32   | 47   | 7    |  |
| Transfers                           | 2    | 24   | 1    | 0    |  |

#### Post-authorisation: variations and transfers submitted



| Renewals — applications |      |      |      |      |  |
|-------------------------|------|------|------|------|--|
|                         | 2012 | 2013 | 2014 | 2015 |  |
| Submitted               | 10   | 16   | 10   | 3    |  |
| Positive opinions       | 10   | 14   | 15   | 0    |  |
| Negative opinions       | 0    | 0    | 0    | 0    |  |

| Establishment of MRLs for new substances — applications |   |   |   |   |  |  |  |
|---|---|---|---|---|--|--|--|
| 2012 2013 2014 2  |   |   |   |   |  |  |  |
| Submitted   | 1 | 6 | 4 | 0 |  |  |  |
| Withdrawals   | 1 | 1 | 0 | 0 |  |  |  |
| Positive opinions <sup>1</sup>                          | 1 | 4 | 4 | 1 |  |  |  |
| Negative opinions                                       | 0 | 0 | 0 | 0 |  |  |  |

<sup>&</sup>lt;sup>1</sup> Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs.

| Extensions/modifications of MRLs — applications |       |      |      |      |  |  |
|---|-------|------|------|------|--|--|
|   | 2012  | 2013 | 2014 | 2015 |  |  |
| Submitted                                       | 5     | 6    | 2    | 1    |  |  |
| Withdrawals                                     | 0     | 0    | 0    | 0    |  |  |
| Positive opinions <sup>2</sup>                  | 8 (2) | 4    | 8    | 1    |  |  |
| Negative opinions                               | 0     | 0    | 0    | 0    |  |  |

<sup>&</sup>lt;sup>2</sup> Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs. Re-examination of opinions are indicated in brackets.

# Review of opinions/extrapolations of MRLs – requests from Commission or Member States


|                      | 2012 | 2013 | 2014 | 2015 |
|----------------------|------|------|------|------|
| Submitted            | 0    | 1    | 2    | 0    |
| Opinion <sup>3</sup> | 0    | 4(3) | 2    | 0    |

<sup>&</sup>lt;sup>3</sup> Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional MRLs. Re-examination of opinions are indicated in brackets.

# Substances considered as not falling within the scope of Regulation (EC) No 470/2009 – requests


|                               | 2012 | 2013 | 2014 | 2015 |
|-------------------------------|------|------|------|------|
| Submitted                     | 9    | 16   | 10   | 0    |
| Agreed                        | 6    | 9    | 9    | 3    |
| Not agreed                    | 1    | 2    | 1    | 0    |
| Scientific advice recommended | 0    | 6    | 1    | 0    |

#### **MRL-related submissions**



| MUMS/limited-market classification — requests |      |      |      |      |  |
|---|------|------|------|------|--|
|   | 2012 | 2013 | 2014 | 2015 |  |
| MUMS with financial incentives                | 16   | 10   | 2    | 2    |  |
| MUMS without financial incentives             | 4    | 10   | 20   | 0    |  |
| Not MUMS                                      | 1    | 3    | 7    | 0    |  |






| Arbitrations and referrals           |        |        |        |      |
|--------------------------------------|--------|--------|--------|------|
|                                      | 2012   | 2013   | 2014   | 2015 |
| Arbitrations and referrals submitted | 12     | 10     | 7      | 0    |
| Opinions <sup>3</sup>                | 11 (1) | 13 (3) | 10 (1) | 0    |

<sup>&</sup>lt;sup>3</sup> Re-examination of opinions in brackets.

# Arbitrations and referrals submitted and opinions



# CVMP opinions in 2015 on medicinal products for veterinary use

# Positive opinions

| Product  Invented name  INN/Common name  | Marketing<br>authorisation<br>holder | Therapeutic area  • Target species  • Summary of indication                       | <ul><li>EMA/CVMP</li><li>Validation</li><li>Opinion</li><li>Active time</li><li>Clock stop</li></ul> | European Commission Opinion received Transmission to EC Decision Notification Official Journal |
|--|--------------------------------------|---|--|--|
| <ul> <li>Coliprotec F4</li> <li>Porcine post-weaning<br/>diarrhoea vaccine<br/>(live)</li> </ul> | Prevtec Microbia     GmbH            | <ul><li>Pig</li><li>Vaccine<br/>against post-<br/>weaning<br/>diarrhoea</li></ul> | <ul><li>12/03/2014</li><li>15/01/2015</li><li>210</li><li>99</li></ul>                               | • 15/01/2015<br>• 11/02/2015   |

# CVMP opinions in 2015 on establishment of MRLs

# Positive opinions

| Product • Substance                  | Target species                | <ul><li>EMA/CVMP</li><li>Validation</li><li>Opinion</li><li>Active time</li><li>Clock stop</li></ul> | <ul><li>European Commission</li><li>Opinion received</li><li>Regulation</li><li>Official Journal</li></ul> |
|--------------------------------------|-------------------------------|--|--|
| Sisapronil                           | Bovine, caprine               | <ul><li>12/12/2013</li><li>15/01/2015</li><li>210</li><li>190</li></ul>                              | • 23/01/2015   |
| Diethylene glycol<br>monoethyl ether | All food producing<br>species | <ul><li>17/09/2014</li><li>12/02/2015</li><li>148</li><li>0</li></ul>                                | • 16/02/2015   |

# **Arbitrations and referrals in 2015**

# Ongoing procedures

| Type of procedure   | Olock start CVMP opinion | Product  • Product name  • INN   |
|---|--------------------------|--|
| <ul> <li>Procedure under Article<br/>30(3) of Regulation<br/>726/2004</li> </ul>        | • 10/01/2013             | <ul><li>Not applicable</li><li>Lidocaine</li></ul>   |
| <ul> <li>Referral under Article 35<br/>of Directive 2001/82/EC</li> </ul>               | • 10/04/2013             | <ul> <li>All veterinary medicinal products<br/>containing altrenogest to be<br/>administered orally to pigs and horses</li> <li>Altrenogest</li> </ul> |
| <ul> <li>Referral under Article</li> <li>33(4) Directive</li> <li>2001/82/EC</li> </ul> | • 08/10/2014             | <ul><li>Gutal 1000 g/kg premix for medicated<br/>feeding stuff for pigs</li><li>Zinc oxide</li></ul>   |
| • Procedure under Article 33(4) of Directive 2001/82/EC                                 | • 05/11/2014             | <ul> <li>Coglapix vakcina A.U.V. suspension for injection for pigs</li> <li>Actinobacillus pleuropneumoniae strains serotype 1 and 2</li> </ul>        |

# **Guidelines and working documents in 2015**

# **CVMP** quality

| Reference number                                  | Document title  | Status                |
|---|---|-----------------------|
| [Published on EMA website after adoption at CHMP] | Question and Answer document on plastic containers for eye drops. | Adopted February 2015 |

#### CVMP safety

| Reference number    | Document title   | Status               |
|---------------------|--|----------------------|
| EMA/CVMP/90250/2010 | Guideline on risk characterisation and assessment of MRLs for biocides used in animal husbandry. | Adopted January 2015 |

#### **CVMP** antimicrobials

| Reference number         | Document title  | Status  |
|--------------------------|---|---|
| EMA/CVMP/AWP/401740/2013 | Reflection paper on the risk of antimicrobial resistance transfer from companion animals.   | Adopted January 2015  |
| EMA/CVMP/EWP/261180/2012 | Revised guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances.  | Adopted for consultation<br>February 2015<br>(End of consultation, 31 May<br>2015)    |
| EMA/CVMP/AWP/706442/2013 | Draft new guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food-producing animals. | Adopted for consultation<br>February 2015<br>(End of consultation, 31<br>August 2015) |

# **CVMP** immunologicals

| Reference number          | Document title                  | Status                         |
|---------------------------|---------------------------------|--------------------------------|
| EMA/CVMP/IWP/205351/2006- | Draft revised guideline on the  | Adopted for consultation       |
| Rev.1                     | procedure to be followed when a | January 2015                   |
|                           | batch of a vaccine finished     |                                |
|                           | product is suspected to be      | (End of consultation, 30 April |
|                           | contaminated with bovine viral  | 2015)                          |
|                           | diarrhoea virus (BVDV).         |                                |

# International harmonisation

| Reference number          | Document title   | Status                |
|---------------------------|--|-----------------------|
| EMA/CVMP/VICH/463199/2009 | VICH GL48(R): Revised guideline on Studies to Evaluate the Metabolism and Residues Kinetics of Veterinary Drugs in Human Food-producing Animals: Marker Residue Depletion Studies to establish Product Withdrawal Periods. | Adopted February 2015 |
| EMA/CVMP/VICH/463202/2009 | VICH GL49(R): Revised guideline on Studies to Evaluate the Metabolism and Residues Kinetics of Veterinary Drugs in Human Food-producing Animals: Validation of Analytical Methods used in Residue Depletion Studies.       | Adopted February 2015 |